ValiRx plc

Default features description for sign up page.

Careers

Collaborative Pipeline

Board & Management Team

Privacy Policy

How we work

Strategy & Vision

Updates

Analyst Research

AIM Rule 26

Share Price Information

Reports, AGMs & Presentations

Regulatory News

Webinars

Partnering & Useful Links

Therapeutic Areas

Inaphaea Biolabs

Evaluation Pipeline

Our Pipeline

Home

Contact Us

DM Sans

We are thrilled to announce that ValiRx subsidiary, ValiSeek Limited, has entered into an exclusive worldwide Option Agreement with private UK pharmaceutical company Ambrose Healthcare Ltd for rights to develop and License VAL401.

Ambrose Healthcare Ltd is a specialist pharmaceutical company, developing new treatments for rare diseases and patients managed in hospitals and specialist care.

Under the Option Agreement, Ambrose has a 12-month period of exclusivity under which it may exercise the option to execute a global, exclusive license VAL401 from ValiSeek under pre-agreed terms.

Speaking about the agreement, ValiRx CEO Dr Suzy Dilly comments:

"I’m delighted to have agreed this path to development of VAL401 with Ambrose. I’m looking forward to seeing the project develop under Ambrose’s experienced oversight, combining clinical development and commercial experience.”

Dr Suzanne Dilly discusses the VAL401 license agreement with Ambrose Healthcare.

ValiRx - Agreement to License VAL401